A Review of Temporal Interference, Nanoparticles, Ultrasound, Gene Therapy, and Designer Receptors for Parkinson Disease

Overview

Journal NPJ Parkinsons Dis

Date 2024 Oct 24

PMID 39443513

Authors

A D Currie

J K Wong

M S Okun

Affiliations

Soon will be listed here.

Abstract

In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management. We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs. These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.

Citing Articles

Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.

Sharma H, Narayanan K, Ghosh S, Singh K, Rehan P, Amist A Biomimetics (Basel). 2025; 10(1).

PMID: 39851741 PMC: 11762342. DOI: 10.3390/biomimetics10010025.

References

Roet M, Hescham S, Jahanshahi A, Rutten B, Anikeeva P, Temel Y . Progress in neuromodulation of the brain: A role for magnetic nanoparticles?. Prog Neurobiol. 2019; 177:1-14. DOI: 10.1016/j.pneurobio.2019.03.002. View

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View

Chen R, Romero G, Christiansen M, Mohr A, Anikeeva P . Wireless magnetothermal deep brain stimulation. Science. 2015; 347(6229):1477-80. DOI: 10.1126/science.1261821. View

Guduru R, Liang P, Hong J, Rodzinski A, Hadjikhani A, Horstmyer J . Magnetoelectric 'spin' on stimulating the brain. Nanomedicine (Lond). 2015; 10(13):2051-61. PMC: 4910966. DOI: 10.2217/nnm.15.52. View

Christine C, Richardson R, Van Laar A, Thompson M, Fine E, Khwaja O . Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2021; 98(1):e40-e50. PMC: 8726573. DOI: 10.1212/WNL.0000000000012952. View

Muller B, Assmus J, Herlofson K, Larsen J, Tysnes O . Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord. 2013; 19(11):1027-32. DOI: 10.1016/j.parkreldis.2013.07.010. View

Bansal A, Shikha S, Zhang Y . Towards translational optogenetics. Nat Biomed Eng. 2022; 7(4):349-369. DOI: 10.1038/s41551-021-00829-3. View

Martin D . Regulatory properties of brain glutamate decarboxylase. Cell Mol Neurobiol. 1987; 7(3):237-53. PMC: 11567405. DOI: 10.1007/BF00711302. View

Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020; 10:1663. PMC: 7511634. DOI: 10.3389/fonc.2020.01663. View

10.

Rezai A, DHaese P, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K . Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease. N Engl J Med. 2024; 390(1):55-62. DOI: 10.1056/NEJMoa2308719. View

11.

Wang J, Aryal M, Zhong Q, Vyas D, Airan R . Noninvasive Ultrasonic Drug Uncaging Maps Whole-Brain Functional Networks. Neuron. 2018; 100(3):728-738.e7. PMC: 6274638. DOI: 10.1016/j.neuron.2018.10.042. View

12.

Santos-Garcia D, de la Fuente-Fernandez R . Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. J Neurol Sci. 2013; 332(1-2):136-40. DOI: 10.1016/j.jns.2013.07.005. View

13.

Sonabend A, Gould A, Amidei C, Ward R, Schmidt K, Zhang D . Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023; 24(5):509-522. PMC: 10256454. DOI: 10.1016/S1470-2045(23)00112-2. View

14.

Deisseroth K, Feng G, Majewska A, Miesenbock G, Ting A, Schnitzer M . Next-generation optical technologies for illuminating genetically targeted brain circuits. J Neurosci. 2006; 26(41):10380-6. PMC: 2820367. DOI: 10.1523/JNEUROSCI.3863-06.2006. View

15.

Alcacer C, Andreoli L, Sebastianutto I, Jakobsson J, Fieblinger T, Cenci M . Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. J Clin Invest. 2017; 127(2):720-734. PMC: 5272195. DOI: 10.1172/JCI90132. View

16.

Lang A, Lozano A, Montgomery E, Duff J, Tasker R, Hutchinson W . Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med. 1997; 337(15):1036-42. DOI: 10.1056/NEJM199710093371503. View

17.

Chen J, Guo Z, Tian H, Chen X . Production and clinical development of nanoparticles for gene delivery. Mol Ther Methods Clin Dev. 2016; 3:16023. PMC: 4822651. DOI: 10.1038/mtm.2016.23. View

18.

Kim T, Kim H, Choi W, Lee Y, Pyo J, Lee J . Deep brain stimulation by blood-brain-barrier-crossing piezoelectric nanoparticles generating current and nitric oxide under focused ultrasound. Nat Biomed Eng. 2022; 7(2):149-163. DOI: 10.1038/s41551-022-00965-4. View

19.

McColgan P, Thobhani A, Boak L, Schobel S, Nicotra A, Palermo G . Tominersen in Adults with Manifest Huntington's Disease. N Engl J Med. 2023; 389(23):2203-2205. DOI: 10.1056/NEJMc2300400. View

20.

Christine C, Bankiewicz K, Van Laar A, Richardson R, Ravina B, Kells A . Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019; 85(5):704-714. PMC: 6593762. DOI: 10.1002/ana.25450. View